A 12-year-old patient with high-risk acute myeloid leukemia (AML; FAB classification M0, translocation t(6;11) with KMT2A::MLLT4 fusion) in complete molecular remission after chemotherapy according to the AML-BFM 2019 protocol, was admitted for allo-HSCT to the Stem Cell Transplantation Unit, Department of Pediatrics, Jena University Hospital, in May 2023. Here, KMT2A is linked to acute myeloid leukemia.